We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.
- Authors
Büyükkurt, Nurhilal; Özcan, Mehmet Ali; Ergene, Ülkü; Payzın, Bahriye; Tunalı, Sunay; Demirkan, Fatih; Özsan, Hayri; Pişkin, Özden; Ündar, Bülent
- Abstract
Objective: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the FcγRIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we investigated the impact of FcγRIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS). Materials and Methods: Patients from 3 centers in the Aegean region of Turkey who had newly diagnosed CD20-positive DLBCL were enrolled in the study. The single nucleotide polymorphisms of the FcγRIIIA gene were analyzed by real time- PCR. The response to treatment was determined in the middle and at the end of the protocol. During 2 years of follow-up, the patients were clinically and radiologically evaluated for disease status every 3 months. Results: Thirty-six patients were included in the study and the distributions of F/F, V/F, and V/V types of alleles of FcγRIIIA were 25%, 50%, and 25%, respectively. Twenty-seven patients were considered as evaluable according to ORR and OS. The patients' ORR was 87.5%, 100%, and 50% in the F/F, V/F, and V/V allele groups, respectively. We did not establish any statistically significant differences among the 3 alleles groups in respect to ORR (p=0.93). The OS within 2 years in the F/F, V/F, and V/V allele groups was 62.5%, 100%, and 100%, respectively. The OS in the F/F allele group was found to be lower than in the other 2 allele groups (p=0.01). Conclusion: The distribution of gene polymorphisms in our study group was similar to those of previous studies. While ORR was similar between the groups, our results highlight a lower OS in F/F patients compared to other allele groups of FcγRIIIA.
- Subjects
TURKEY; RITUXIMAB; ALLELES; B cell lymphoma; CANCER chemotherapy; GENES; GENETIC polymorphisms; LONGITUDINAL method; MEDICAL cooperation; SCIENTIFIC observation; POLYMERASE chain reaction; RESEARCH; DESCRIPTIVE statistics; PROGNOSIS
- Publication
Turkish Journal of Hematology, 2015, Vol 32, Issue 2, p152
- ISSN
1300-7777
- Publication type
Article
- DOI
10.4274/tjh.2013.0367